OPKO Health, Inc.

NasdaqGS:OPK Stock Report

Market Cap: US$1.1b

OPKO Health Management

Management criteria checks 4/4

OPKO Health's CEO is Phil Frost, appointed in Mar 2007, has a tenure of 18.67 years. total yearly compensation is $2.16M, comprised of 44.4% salary and 55.6% bonuses, including company stock and options. directly owns 4.39% of the company’s shares, worth $46.84M. The average tenure of the management team and the board of directors is 10.2 years and 16.6 years respectively.

Key information

Phil Frost

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage44.37%
CEO tenure18.7yrs
CEO ownership4.4%
Management average tenure10.2yrs
Board average tenure16.6yrs

Recent management updates

Recent updates

OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Not Quite Adding Up

Sep 19
OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Not Quite Adding Up

OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy

Jun 11

What OPKO Health, Inc.'s (NASDAQ:OPK) P/S Is Not Telling You

May 24
What OPKO Health, Inc.'s (NASDAQ:OPK) P/S Is Not Telling You

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

May 01
OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
User avatar

Phase 1 Trials With Merck And Pfizer Will Unlock New Opportunities

Progress in ModeX's pipeline and the Merck collaboration could drive growth in the Pharmaceuticals segment with potential revenue impacts from trials and commercialization.

The OPKO Health, Inc. (NASDAQ:OPK) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 05
The OPKO Health, Inc. (NASDAQ:OPK) Full-Year Results Are Out And Analysts Have Published New Forecasts

OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Could Signal Some Risk

Jan 14
OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Could Signal Some Risk

OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 09
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Not Enough To Keep OPKO Health Flying

Aug 28

OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

Dec 30
OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

Is OPKO Health (NASDAQ:OPK) A Risky Investment?

Oct 03
Is OPKO Health (NASDAQ:OPK) A Risky Investment?

OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up

Jul 24
OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up

Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?

Jun 07
Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?

Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?

Jan 04
Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?

OPKO Health: Assessing If Significant Potential Can Be Realized

Sep 15

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

Sep 05
OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

CEO Compensation Analysis

How has Phil Frost's remuneration changed compared to OPKO Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$180m

Jun 30 2025n/an/a

-US$177m

Mar 31 2025n/an/a

-US$39m

Dec 31 2024US$2mUS$960k

-US$53m

Sep 30 2024n/an/a

-US$134m

Jun 30 2024n/an/a

-US$243m

Mar 31 2024n/an/a

-US$252m

Dec 31 2023US$2mUS$960k

-US$189m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$209m

Mar 31 2023n/an/a

-US$291m

Dec 31 2022US$972kUS$960k

-US$328m

Sep 30 2022n/an/a

-US$317m

Jun 30 2022n/an/a

-US$202m

Mar 31 2022n/an/a

-US$117m

Dec 31 2021US$2mUS$960k

-US$30m

Sep 30 2021n/an/a

US$76m

Jun 30 2021n/an/a

US$71m

Mar 31 2021n/an/a

US$121m

Dec 31 2020US$2mUS$960k

US$31m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$200m

Mar 31 2020n/an/a

-US$293m

Dec 31 2019US$1mUS$960k

-US$315m

Sep 30 2019n/an/a

-US$279m

Jun 30 2019n/an/a

-US$244m

Mar 31 2019n/an/a

-US$191m

Dec 31 2018US$2mUS$960k

-US$153m

Compensation vs Market: Phil's total compensation ($USD2.16M) is below average for companies of similar size in the US market ($USD3.48M).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.

CEO

Phil Frost (89 yo)

18.7yrs
Tenure
US$2,163,800
Compensation

Dr. Phillip Frost, also known as Phil, M.D., Ph D., is Director of Non-Invasive Monitoring Systems, Inc. since June 01, 2023. He has been the Chairman, Chief Executive Officer and Director of OPKO Health,...

Leadership Team

NamePositionTenureCompensationOwnership
Phillip Frost
Chairman & CEO18.7yrsUS$2.16m4.39%
$ 46.8m
Jane Hsiao
Vice Chairman & Chief Technical Officer18.8yrsUS$2.07m4.32%
$ 46.0m
Elias Zerhouni
President & Vice Chairman3.5yrsUS$2.07m2.66%
$ 28.4m
Adam Logal
Senior VP & CFO11.7yrsUS$1.81m0.023%
$ 249.1k
Steven Rubin
Executive VP of Administration & Director18.5yrsUS$1.85m0.81%
$ 8.6m
Gary Nabel
Chief Information Officer & Directorless than a yearno data5.25%
$ 56.0m
Arie Gutman
President of APIno datano datano data
Akhtar Ashfaq
Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal8.7yrsno datano data
Giovanni Abbadessa
Chief Medical Officer of ModeX1.1yrsno datano data
John Mascola
Chief Scientific Officer of ModeX3.8yrsno datano data
Charles Bishop
Chief Executive Officer of OPKO Renal12.7yrsno datano data
Hans Berner
President of OPKO Health Iberoamericano datano datano data
10.2yrs
Average Tenure
72yo
Average Age

Experienced Management: OPK's management team is seasoned and experienced (10.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Phillip Frost
Chairman & CEO18.7yrsUS$2.16m4.39%
$ 46.8m
Jane Hsiao
Vice Chairman & Chief Technical Officer18.8yrsUS$2.07m4.32%
$ 46.0m
Elias Zerhouni
President & Vice Chairman3.5yrsUS$2.07m2.66%
$ 28.4m
Steven Rubin
Executive VP of Administration & Director18.8yrsUS$1.85m0.81%
$ 8.6m
Gary Nabel
Chief Information Officer & Director3.5yrsno data5.25%
$ 56.0m
Roger Medel
Independent Director4.9yrsUS$62.40k0%
$ 0
Richard Pfenniger
Lead Independent Director17.8yrsUS$119.80k0.042%
$ 451.7k
Richard Krasno
Independent Director8.8yrsUS$84.90k0.013%
$ 143.6k
John Paganelli
Independent Director21.9yrsUS$77.40k0.051%
$ 547.0k
Prem Lachman
Independent Director4.7yrsUS$84.90k0%
$ 0
Lin-Tsing Yu
Independent Director16.6yrsUS$54.90k0.0087%
$ 92.4k
Richard Lerner
no datano datano data
16.6yrs
Average Tenure
78yo
Average Age

Experienced Board: OPK's board of directors are seasoned and experienced ( 16.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/05 20:38
End of Day Share Price 2025/11/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OPKO Health, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Louise ChenCantor Fitzgerald & Co.
Dana FlandersGuggenheim Securities, LLC